文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

法国和意大利HIV-1经治患者中多拉韦林相关耐药突变的流行率

Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

该研究分析了法国和意大利2012至2017年间9199条HIV-1经治患者的逆转录酶序列,其中381例为NNRTI治疗失败者,评估多拉韦林相关耐药突变的频率。结果显示,NNRTI失败组中至少一种多拉韦林相关耐药突变的总体流行率为34.9%,显著高于总数据集的12.2%(P<0.001),但多拉韦林耐药率仍低于其他常用NNRTI。

要点

  • 经治患者中至少一种多拉韦林相关耐药突变的流行率为12.2%,NNRTI失败组为34.9%。
  • NNRTI失败组中多数多拉韦林相关突变的频率显著更高(P<0.05),但M230I/L和K103N+Y181C例外。
  • 多拉韦林耐药率低于其他常用NNRTI,提示其具有独特的耐药模式。

核心结论

  • 经治患者中多拉韦林耐药总体低于其他NNRTI,NNRTI失败者中仍较高但低于其他NNRTI。

研究设计与样本

  • 研究分析了9199条HIV-1逆转录酶序列,来自法国和意大利2012至2017年经治患者,其中381例为NNRTI失败者。

主要发现

  • 总数据集与NNRTI失败组中至少一种多拉韦林相关耐药突变的流行率分别为12.2%和34.9%(P<0.001)。
  • V106A/M频率为0.8% vs 2.6%;V108I为3.3% vs 9.2%;Y188L为1.2% vs 2.6%;G190S为0.3% vs 2.1%;F227C/L/V为0.5% vs 1.8%;L234I为0.1% vs 0.5%;K103N+P225H为2.9% vs 4.7%;K103N+L100I为1.7% vs 3.9%。
  • M230I/L频率为2.8% vs 0%;K103N+Y181C为3.9% vs 3.9%,两者在组间无显著差异。
  • 常见NNRTI突变V90I、K101E/P、K103N/S、E138A/G/K/Q/R/S、Y181C/I/V和G190A/E/S/Q的流行率分别为8.9%、7.9%、28.6%、12.6%、14.2%和8.9%。

关键数值与推荐

  • 多拉韦林相关耐药突变定义为:V106A/M、V108I、Y188L、G190S、F227C/L/V、M230I/L、L234I、P236L、K103N+Y181C、K103N+P225H、K103N+L100I。

临床怎么用

  • 对于NNRTI经治失败患者,多拉韦林相关耐药突变流行率较高,使用多拉韦林前应进行耐药检测。
  • 多拉韦林耐药率低于其他NNRTI,可能作为经治患者的治疗选择,但需结合耐药结果个体化决策。

局限性

  • 研究基于数据库序列,可能不能完全代表临床人群。
  • 仅纳入法国和意大利2012至2017年数据,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Doravirine, a novel NNRTI, selects for specific mutations in vitro, including mutations at reverse transcriptase (RT) positions 106, 108, 188, 227, 230 and 234. The aim of this study was to examine the prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients. METHODS: Doravirine-associated resistance mutations identified in vitro or in vivo were studied in a set of 9199 HIV-1 RT sequences from HIV-1 antiretroviral-experienced patients, including 381 NNRTI-failing patients in France and Italy between 2012 and 2017. The following mutations were considered as resistance mutations: V106A/M, V108I, Y188L, G190S, F227C/L/V, M230I/L, L234I, P236L, K103N + Y181C, K103N + P225H and K103N + L100I. RESULTS: The frequencies of doravirine-associated resistance mutations (total dataset versus NNRTI-failing patients) were: V106A/M, 0.8% versus 2.6%; V108I, 3.3% versus 9.2%; Y188L, 1.2% versus 2.6%; G190S, 0.3% versus 2.1%; F227C/L/V, 0.5% versus 1.8%; M230I/L, 2.8% versus 0%; L234I, 0.1% versus 0.5%; K103N + Y181C, 3.9% versus 3.9%; K103N + P225H, 2.9% versus 4.7%; and K103N + L100I, 1.7% versus 3.9%, with a significantly higher proportion of these mutations in the NNRTI-failing group (P < 0.05), except for M230I/L and K103N + Y181C. The overall prevalence of sequences with at least one doravirine-associated resistance mutation was 12.2% and 34.9% in the total dataset and NNRTI-failing patients (P < 0.001), respectively. In comparison, the prevalence of the common NNRTI mutations V90I, K101E/P, K103N/S, E138A/G/K/Q/R/S, Y181C/I/V and G190A/E/S/Q were higher (8.9%, 7.9%, 28.6%, 12.6%, 14.2% and 8.9%, respectively). CONCLUSIONS: These results suggest that doravirine resistance in antiretroviral-experienced patients generally and specifically among NNRTI-failing patients is lower than resistance to other NNRTIs currently used, confirming its distinguishing resistance pattern.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Soulie C, Santoro MM, Storto A, et al. Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy. J Antimicrob Chemother. 2020. PMID: 31976534. doi:10.1093/jac/dkz553

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。